
Guselkumab Shown to Reduce Structural Damage in Psoriatic Arthritis
Positive topline results were announced from a phase 3b trial evaluating the efficacy and safety of guselkumab (Tremfya) in adult patients with active psoriatic arthritis (PsA), Johnson and Johnson announced in a release.1 Results from the APEX study ( …